Specifications
Applications
Application Notes
WB: 1:200-1000
ELISA: 1:200-2000
Target
Alternative Names
HPV; L1; major capsid L1 protein; HPV-52; HPV-52 capsid; HPV52 capsid protein; HPV52 L1; HPV52 major capsid protein L1; Human papillomavirus type 52 L1; Human papillomavirus type 152 major capsid protein L1; Major capsid protein; Major capsid protein L1; Human papillomavirus
Citations
Publication ()
Have you cited CABT-B8799 in a publication?
Let us know and earn a reward for your research.
Expression, purification, and characterization of self-assembly virus-like particles of capsid protein L1 HPV 52 in Pichia pastoris GS115
Chindy Nur Rosmeita, Sri Budiarti, Apon Zaenal Mustopa, Ela Novianti, Sri Swasthikawati, Sheila Chairunnisa, Ai Hertati, Maritsa Nurfatwa, Nurlaili Ekawati, Nurhasni Hasan
J Genet Eng Biotechnol2023 NovPubMed ID: 37981617Read Article
Applications: WB
Reactive species: HPV52
"Abstract: Background: Cervical cancer caused by the human papillomavirus (HPV) is one of the most frequent malignances globally. HPV 52 is a high-risk cancer-causing genotype that has been identified as the most prevalent type in Indonesia. Virus-like particles (VLP)-based vaccinations against HPV infection could benefit from self-assembled VLP of L1 capsid protein."
Article snippet: An anti-L1 HPV 52 antibody (Creative Diagnostics, USA) was used as the positive control. 
Figure 1. Western blot analysis of the HPV 52 L1 protein in the fractions collected from the cation exchange column.
Medium Optimization for Recombinant Human Papillomavirus Type 52 L1 Protein Production in Pichia pastoris GS115 Platform on Bioreactor Scale
Apon Zaenal Mustopa, Febriyanti Nur Amani, Herman Irawan, Ela Novianti, Sri Swasthikawati, Nurlaili Ekawati, Maritsa Nurfatwa, Daniel Joko Wahyono, Ario Betha Juanssilfero, Jendri Mamangkey, Yudi Purnomo, Ai Hertati, Hans Wijaya, Kartika Sari Dewi, Ratih Asmana Ningrum
Applications: ELISA
Reactive species: HPV52
"Abstract: Human papillomavirus (HPV) stands as the primary etiological agent in the development of invasive cervical cancer worldwide. The L1 protein is a pivotal constituent of prophylactic HPV vaccines. Notably, HPV type 52 is one of the most prevalent genotypes found in squamous cell carcinoma cases in Indonesia. This research endeavor aims to enhance the productivity of recombinant HPV-52 L1 protein by optimizing the culture conditions of P. pastoris GS115 cells. In this study, we conducted trials employing 17 different media variants to optimize the expression of recombinant HPV-52 L1 protein. The results from small-scale experiments revealed three media, namely SYN6.10, BMMY, and SYN6.1, which exhibited promising yields of recombinant HPV-52 L1 protein as assessed through ELISA or immunoassay analysis. We succeeded in refining the SYN6.10 derivative, denoted as SYN6.10b, specifically designed for use in 1-L and 5-L bioreactors. This achievement was realized by adjusting Trace Element Solution (TES) and Vitamin Solution (VS) concentrations and implementing a methanol fed-batch phase with the addition of 0.3% methanol after 24 and 48 hours of fermentation in the P. pastoris medium. Further visualizations through SDS-PAGE and western blot analysis confirmed the protein after 72 hours of fermentation in a 1-L bioreactor using the SYN6.10b medium. In conclusion, the SYN6.10b medium required a 72 hours fermentation period to successfully express recombinant HPV-52 L1 protein in the P. pastoris platform."
Article snippet: The HPV 52 L1 protein was quantified by ELISA using specific antibodies (Creative Diagnostic, CABT B8799). 
Figure 1. SDS-PAGE (A) and Western-blot 55 kDa shown by red arrow (B) in 5-L bioreactor.
COA
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
Loading ......
